Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the ...

One mom noticed how rough third grade had been for her daughter both emotionally and socially. Here's what she learned.

ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment – – ...

SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and ...

-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- ...

Researchers at Mayo Clinic have unveiled a novel function of TRAILshort, a protein that inhibits T-cell activity, thereby diminishing immune responses to cancer and infections. The findings, published ...

Clinical data from the HERCULES trial show that tolebrutinib reduces six-month confirmed disability progression by 31% in non ...

Tyra Biosciences' dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3 profile. Read ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

Showing up at a filming location offers something social media can’t: the possibility that a parasocial relationship might be reciprocated.

Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 ...

MANILA, Philippines — While they are concerned over the spread of wrong information — particularly regarding the spliced ...